US EditionPublished • loading... • Updated
Tourmaline Bio Enters Into Agreement to Be Acquired by Novartis AG
Novartis will acquire Tourmaline Bio for $1.4 billion to gain pacibekitug, a Phase 3 ready anti-IL-6 therapy targeting systemic inflammation in cardiovascular disease.
- In Basel on September 9, 2025, Novartis AG said it will acquire Tourmaline Bio, Inc. for $48.00 per share, valuing the company at approximately $1.4 billion.
- Novartis cited clinical readiness and strategic fit, with Pacibekitug previously studied in approximately 450 participants, supporting its potential in cardiovascular indications.
- Study results and product properties demonstrate that pacibekitug, studied in approximately 450 participants, has a long half-life enabling once-quarterly dosing, with Phase 2 TRANQUILITY study results released May 20, 2025 showing median hs-CRP reductions of 85%.
- Both companies' Boards unanimously approved the deal, and Novartis will commence a tender offer via a Novartis indirect wholly owned subsidiary to buy shares at $48.00 each, with completion expected in the fourth quarter of 2025.
- Novartis framed the deal as expanding its cardiovascular pipeline and reaches more than 250 million people worldwide; it noted forward-looking disclaimers with no guarantee of clinical success.
Insights by Ground AI
22 Articles
22 Articles
An acquired drug will complete the current portfolio of medicines for cardiovascular diseases of Novartis
·Milan, Italy
Read Full Article
Coverage Details
Total News Sources22
Leaning Left2Leaning Right2Center5Last UpdatedBias Distribution56% Center
Bias Distribution
- 56% of the sources are Center
56% Center
L 22%
C 56%
R 22%
Factuality
To view factuality data please Upgrade to Premium
